The 12-month period prevalence and cardiac manifestations of HIV in patients with acute coronary syndrome at a tertiary hospital in Cape Town, South Africa: a retrospective cross-sectional study

Camilla Pennefather
Tonya Esterhuizen
Anton Doubell
Eric H. Decloedt (ericdecloedt@sun.ac.za)

Research

**Keywords:** Acute coronary syndrome, HIV infection, risk factors, cardiac manifestations, prevalence

**DOI:** https://doi.org/10.21203/rs.3.rs-34814/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

HIV-positive patients are increasingly being affected by non-communicable diseases such as coronary artery disease (CAD). Data from high-income countries (HICs) indicate that HIV-positive patients have different risk-factor profiles for acute coronary syndrome (ACS) as well as different cardiac manifestations of this syndrome compared to HIV-negative patients. There is limited data from Sub-Saharan Africa (SSA), and particularly from South Africa with the biggest HIV epidemic in the world. The objective of this study was to determine the 12-month period prevalence of HIV in patients with ACS and to compare the risk-factor profile, ACS presentation and management between HIV-positive and HIV-negative adults.

Methods

We included all patients hospitalised with ACS from 01 January to 31 December 2018 in a tertiary hospital, Tygerberg Hospital, in Cape Town, South Africa. The HIV-status of all patients was determined using routine clinical records. We performed multivariate conditional logistic regression on HIV-positive and HIV-negative patients (1:3 ratio) to compare the risk factor profile, ACS presentation and management between the groups.

Results

Among 889 patients, 30 (3.4%) were HIV-positive (95% confidence interval (CI): 2.3–4.8). HIV-positive patients were younger, more frequently men, and had a lower prevalence of medical comorbidities and a family history of CAD. They were more likely to present with ST-elevation myocardial infarction (STEMI) [odd’s ratio (OR) (95% CI): 3.12 (1.2–8.4)], and have single-vessel disease [OR (95% CI): 3.03 (1.2–8.0)]. Angiographic and echocardiographic data, as well as management, did not differ between the groups. Among HIV-positive patients, 17 (65%) were virally suppressed (HIV viral load < 200 copies/mL) with a median CD4+ count of 271 cells/mm³. The majority (20, 67%) of HIV-positive patients were receiving antiretroviral therapy at the time of the ACS.

Conclusions

We found an HIV-prevalence of 3.4% (95% CI 2.3–4.8) in adults with ACS in a high endemic HIV region. HIV-positive patients were younger and more likely to present with STEMI and single-vessel disease, but had fewer CAD risk factors, suggesting additional mechanisms for the development of ACS.

Background
The incidence of acute coronary syndrome (ACS) in HIV-positive individuals is increasing [1]. Antiretroviral therapy (ART) treated HIV-positive patients are experiencing fewer HIV-related opportunistic infections and are increasingly being affected by the same age-associated spectrum of atherosclerotic disease, including coronary artery disease (CAD), as the general population [2]. Atherosclerotic disease, however, is emerging about ten years earlier than in their uninfected counterparts, suggesting an alternative pathogenesis in HIV-positive patients [3]. CAD accounts for 8–22% of deaths among the HIV-positive population, making it an important cause of morbidity and mortality [4]. This is in contrast to the pre-ART era, when cardiomyopathies, pancarditis, conduction system abnormalities, pulmonary hypertension leading to heart failure, and neoplastic infiltration were more important cardiac manifestations of HIV infection [5].

Despite much data from Europe and North America, there are limited studies from South Africa, a low and middle-income country (LMIC), reporting on the prevalence of HIV in ACS, as well as the CAD risk factors, cardiac manifestations and management of ACS in these patients [6]. Most studies demonstrate HIV-positive patients with ACS to be younger, predominantly male, likely to smoke but with a lower prevalence of traditional CAD risk factors (diabetes mellitus, hypertension, dyslipidaemia) compared to their HIV-negative counterparts [1]. The increased incidence of ACS in the HIV-positive population suggests additional pathogenic mechanisms including increased survival time, ongoing HIV inflammation, immune-activation and ART-induced metabolic derangements [7, 4]. Chronic HIV-associated inflammation is associated with abnormal lipid profiles independent of ART, unstable plaque morphology, and more severe coronary artery stenosis [8]. Furthermore, it has been shown that HIV-positive patients have increased C-reactive protein, interleukin-6 and D-dimer levels, contributing to a pro-inflammatory and pro-thrombotic environment [5]. HIV-replication and immune-activation causes up-regulation of tissue factor pathways and chronic platelet activation, which may promote atherogenesis and put these patients at an increased risk of thrombotic events [7]. The clinical presentation of HIV-positive patients with CAD seems to be similar to that of the general population, and includes silent ischaemia, stable angina and ACS [7]. ACS is the main clinical presentation, of which ST-segment elevation myocardial infarction (STEMI) is the main sub-type. Non-ST-elevated myocardial infarction (NSTEMI) and unstable angina (UA) are the most common presentations of ACS in HIV-uninfected persons [1].

CAD is no longer a disease affecting just the high-income countries (HICs); LMICs today are experiencing a greater morbidity and mortality from ACS, with the death toll affecting the younger, productive ages more heavily [9]. This is evidenced by the shift from communicable diseases (48.1% prevalence in 2005; 31.3% prevalence in 2016) to non-communicable diseases (42.9% prevalence in 2005; 57.4% prevalence in 2016) as the primary cause of death in South Africans in the last decade[10]. Despite this, HIV still affects 13.1% of the South African population [11]. HIV-positive patients are hypothesised to be at an increased risk for CAD and the combined effect of these two distinct epidemics may have a marked impact on morbidity and life expectancy. [12, 7].

The primary objective of this retrospective cross-sectional study is to estimate the 12-month period prevalence of HIV in a South African population from Cape Town presenting with ACS. We furthermore
describe the CAD risk factors, cardiac manifestations, and management of HIV-positive patients in comparison to HIV-negative patients.

**Methods**

We conducted a retrospective review of all adult patients presenting to Tygerberg Hospital (TBH), Cape Town, from 01 January to 31 December 2018 with ACS. TBH is the largest public-sector tertiary referral hospital in the Cape Town Metropole and serves over 3.4 million people; mostly vulnerable populations from densely populated low-income communities and rural areas. Patients were identified using clopidogrel prescription data from the JAC electronic dispensing system [13]. Patients with the diagnosis of ACS in their medical record as the indication for clopidogrel treatment were included in the study. The diagnosis of ACS was confirmed by reviewing attending physician discharge summaries, and cross-checking the admission records, electrocardiograms (ECGs), troponin levels, echocardiograms and angiogram reports of each patient. Medical records were accessed using the Western Cape Government’s Electronic Content Management system (ECM) and we extracted the HIV status, sex and age of all patients with a clinical diagnosis of ACS to determine the period prevalence. HIV status was obtained from the South African National Health Laboratory Service (NHLS). Patients with repeated ACS-events within the year were only counted once, and their first ACS-event within the year was described. For the cross-sectional description of risk factors, ACS-type and management of the HIV-positive versus HIV-negative patients; we selected three HIV-negative patients (confirmed HIV-negative test result on the NHLS) for every HIV-positive patient (1:3 ratio) (Fig. 1). The HIV-negative patients were chosen by sequentially selecting the next three patients with a negative HIV-test following the HIV-positive patient, by date order of clopidogrel dispensing. We extracted the following CAD variables from the medical records: comorbidities (hypertension, dyslipidaemia, diabetes mellitus), family history of CAD, social risk factors (tobacco-smoking, body mass index > 25 kg/m², ethanol-misuse), the type of ACS (STEMI, NSTEMI and UA), the culprit coronary artery, the region of myocardium involved, single- or multi-vessel coronary artery disease, echocardiographic findings, pharmacological and interventional management of the patients, as well as their serum creatinine concentration on presentation. In the HIV-positive patients we additionally collected CD4⁺ counts, viral loads and ART data. The CD4⁺ count and viral load closest to the date of ACS-event was recorded.

The calculation of the 12-month period prevalence of HIV-positive patients presenting to TBH with ACS in 2018 was determined from the entire 2018 sample using a simple proportion calculation. From this sample, a sub-sample consisting of just those infected with HIV (exposed) and three times the number of exposed with a confirmed negative HIV test (unexposed) were selected for further statistical analysis. Data were analysed using Stata version 11.0 (StatCorp, College Station, TX, USA). Baseline characteristics of exposed and unexposed patients were compared by chi-square tests or 2-sided Fisher’s exact tests for categorical variables and T-tests or Wilcoxon rank-sum tests for continuous variables. Normally distributed data were described using means, medians and standard deviations (SD). 95% confidence intervals (CIs), odds ratios (ORs), and p-values were derived for all appropriate data. Logistic
regression was performed, controlling for age and sex, in order to determine associations between risk factor profile/cardiac manifestations in those presenting with ACS and HIV-status. Adjusted 95% CIs, ORs and \( p \)-values were derived after such adjustment. Statistical significance was set at a \( p \)-value of less than 0.05.

Results

Prevalence of HIV in ACS

We identified 889 patients who presented to TBH in 2018 with the diagnosis of ACS of which 30 patients were HIV-positive to give a 12 month period prevalence of 3.4% (95% CI 2.3–4.8) (Fig. 1).

Baseline characteristics

Thirty HIV-positive ACS patients were compared with 90 randomly selected HIV-negative ACS patients (Table 1). The HIV-positive patients were on average seven years younger, more frequently men, had a lower prevalence of medical comorbidities (hypertension, dyslipidaemia and diabetes mellitus), and a lower prevalence of a family history of CAD, even after adjusting for age and sex. There was no difference in the social risk factor profile of the patients between the two groups. Although statistically nonsignificant, mention is made of the 11 \( \mu \text{mol/L} \) higher median serum creatinine in the HIV-negative sub-group.
Table 1
Characteristics of HIV-positive compared to HIV-negative patients (crude and adjusted)

| Characteristic, n (%) except where specified | HIV+ (n = 30) | HIV- (n = 90) | Crude OR (95% CI) | *adjusted OR (95% CI) | adjusted p-value |
|---------------------------------------------|--------------|--------------|-------------------|-----------------------|-----------------|
| Demographics                                |              |              |                   |                       |                 |
| Age (years), mean (SD)                      | 50 (11.90)   | 57.32 (11.63)| 0.95 (0.91–0.98)  |                       | 0.008#          |
| Male                                        | 20 (66.7%)   | 50 (55.6%)   | 1.60 (0.67–3.80)  |                       | 0.586#          |
| Cardiovascular risk factors                 |              |              |                   |                       |                 |
| Medical comorbidities                        | 20 (66.7%)   | 83 (92.2%)   | 0.17 (0.06–0.50)  | 0.21 (0.07–0.65)      | 0.007           |
| Hypertension                                | 13 (43.3%)   | 64 (71.1%)   | 0.31 (0.13–0.73)  | 0.39 (0.16–0.97)      | 0.044           |
| Dyslipidaemia                                | 7 (23.3%)    | 45 (50.0%)   | 0.30 (0.12–0.78)  | 0.28 (0.11–0.76)      | 0.012           |
| Diabetes mellitus                           | 4 (13.3%)    | 34 (37.8%)   | 0.25 (0.08–0.79)  | 0.31 (0.10–1.00)      | 0.051           |
| Personal history CAD                        | 4 (13.3%)    | 27 (30.0%)   | 0.36 (0.11–1.13)  | 0.48 (0.15–1.60)      | 0.234           |
| Personal history CVA                        | 3 (10.0%)    | 10 (11.1%)   | 0.89 (0.23–3.47)  | 0.70 (0.17–2.93)      | 0.630           |
| PVD                                         | 3 (10.0%)    | 10 (11.1%)   | 0.89 (0.23–3.47)  | 1.08 (0.26–4.51)      | 0.913           |
| Family history CAD                          | 2 (6.7%)     | 18 (20.0%)   | 0.29 (0.06–1.31)  | 0.20 (0.04–0.99)      | 0.048           |
| Social risk factors                         | 25 (83.3%)   | 74 (82.2%)   | 1.08 (0.36–3.25)  | 0.42 (0.11–1.55)      | 0.192           |
| Smoking                                     | 23 (76.7%)   | 67 (74.4%)   | 1.13 (0.43–2.97)  | 0.57 (0.18–1.76)      | 0.329           |
### Table

| Characteristic, n (%) | HIV+ (n = 30) | HIV- (n = 90) | Crude OR (95% CI) | *adjusted OR (95% CI) | adjusted p-value |
|----------------------|--------------|--------------|-------------------|----------------------|-----------------|
| BMI > 25 kg/m²        | 7 (23.3%)    | 29 (32.2%)   | 0.64 (0.25–1.66)  | 0.56 (0.21–1.50)     | 0.249           |
| Ethanol-misuse        | 3 (10.0%)    | 10 (11.1%)   | 0.89 (0.23–3.47)  | 0.60 (0.14–2.45)     | 0.472           |
| Serum creatinine (µmol/L), median (IQR) | 71.5 (59–98) | 82.5 (66–103) | 0.99 (0.97–1.00)  | 0.99 (0.98–1.01)     | 0.361           |

*adjusted odds ratio conditioned on age and sex. #crude p-value. Bolded text = statistically significant.

OR, odds ratio; CI, confidence interval; SD, standard deviation; CAD, coronary artery disease; CVA, cerebrovascular accident; PVD, peripheral vascular disease; BMI, body mass index; IQR, inter-quartile range

### Acute coronary syndrome information

Twenty-three (76.6%) HIV-positive patients presented with a STEMI compared to 48 (53.3%) controls, with HIV-positive patients being 3.12 (95% CI 1.2–8.4) times more likely to present with a STEMI after adjusting for age and sex (Table 2a). Furthermore, HIV-positive patients were 3.03 (95% CI 1.2–8.0) times more likely to have single-vessel disease after adjusting as above (Table 2a). Although statistically nonsignificant, mention can be made of the increased prevalence of left anterior descending (LAD) artery involvement in the HIV-positive group (16 patients; 53.3%) compared to the HIV-negative group (38 patients; 42.2%), translating into more LAD-territory infarcts in the former (Table 2b).
Table 2
a. ACS presentation of HIV-positive compared to HIV-negative patients (crude and adjusted)

| Outcome, n (%) | HIV+ (n = 30) | HIV- (n = 90) | Crude OR (95% CI) | *adjusted OR (95% CI) | Adjusted p-value |
|----------------|---------------|---------------|-------------------|-----------------------|------------------|
| ACS type       |               |               |                   |                       |                  |
| STEMI          | 23 (76.7%)    | 48 (53.3%)    | 2.88 (1.12–7.37)  | 3.12 (1.16–8.40)      | 0.024            |
| NSTEMI (reference) | 7 (23.3%)   | 32 (35.6%)    |                   |                       |                  |
| UA (reference) | 0 (0.00)      | 10 (8.3%)     |                   |                       |                  |
| Single/multi-vessel disease |       |               |                   |                       |                  |
| Single-vessel  | 16 (53.3%)    | 19 (21.1%)    | 4.27 (1.78–10.27) | 3.03 (1.16–7.96)      | 0.024            |
| Multi-vessel (reference) | 14 (46.7%) | 71 (78.9%)    |                   |                       |                  |

*adjusted odds ratio conditioned on age and sex. Bolded text = statistically significant. OR, odds ratio; CI, confidence interval; ACS, acute coronary syndrome; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina.
### Table 2
b. Angiographic data and management of HIV-positive compared to HIV-negative patients

| Outcome, n (%) | HIV+ (n = 30) | HIV- (n = 90) | p-value |
|---------------|--------------|--------------|---------|
| Culprit coronary artery | | | |
| Left main stem | 0 (0.0%) | 2 (2.2%) | 1 |
| Left anterior descending | 16 (53.3%) | 38 (42.2%) | 0.299 |
| Diagonal (1st branch) | 1 (3.3%) | 5 (5.6%) | 1.000 |
| Circumflex | 4 (13.3%) | 8 (8.9%) | 0.492 |
| Oblique marginal (1st branch) | 1 (3.3%) | 3 (3.3%) | 1.000 |
| Right coronary artery | 6 (20.0%) | 25 (27.8%) | 0.476 |
| Other | 1 (3.3%) | 1 (1.1%) | 0.439 |
| Region affected by STEMI | | | |
| Antero-septal | 13 (56.5%) | 26 (54.2%) | 1 |
| Lateral | 9 (39.1%) | 11 (22.9%) | 0.171 |
| High-lateral | 1 (4.4%) | 4 (8.3%) | 1 |
| Outcome, n (%)         | HIV+ (n = 30) | HIV- (n = 90) | p-value |
|------------------------|---------------|---------------|---------|
| Inferior               | 9 (39.1%)     | 22 (45.8%)    | 0.620   |
| Posterior              | 2 (8.7%)      | 8 (16.7%)     | 0.482   |
| Right ventricle        | 1 (4.4%)      | 2 (4.2%)      | 1       |
| Other                  | 0 (0.0%)      | 1 (2.1%)      | 1       |
| Radiological investigations | 22 (73.3%) | 77 (85.6%)    | 0.165   |
| Echocardiogram         | 1 (3.3%)      | 6 (6.7%)      | 0.670   |
| MRI                    | 17 (73.9%)    | 30 (62.5%)    | 0.341   |
| Intervention in those with STEMI | 2 (8.7%) | 5 (10.4)     | 0.820   |
| Thrombolysis           | 30 (100.0%)   | 90 (100.0%)   | 1       |
| PCI                    | 26 (86.7%)    | 79 (87.8%)    | 1       |
| Conservative           | 1 (3.3%)      | 7 (7.8%)      | 0.678   |
| Discharge medication   | 30 (100.0%)   | 86 (95.6%)    | 0.571   |
| Antiplatelet           | 28 (93.3%)    | 90 (100.0%)   | 0.061   |
| Angiotensin converting enzyme-inhibitor | 25 (92.6%) | 88 (97.8%)    | 0.227   |
| Angiotensin receptor blocker | 2 (7.4%)   | 2 (2.2%)      | 0.227   |
| Beta-blocker           | 0 (0.0%)      | 6 (6.7%)      | 0.335   |
| Statin                 | 0 (0.0%)      | 7 (7.8%)      | 0.190   |
| Simvastatin            | 5 (16.7%)     | 17 (18.9%)    | 1       |
| Atorvastatin           | 1 (3.3%)      | 1 (1.1%)      | 0.439   |
| Nitrate                |               |               |         |
| Calcium-channel blocker|               |               |         |
| Thiazide diuretic      |               |               |         |
| Loop diuretic          |               |               |         |
| Potassium-sparing diuretic |         |               |         |
STEMI, ST-elevation myocardial infarction; MRI, magnetic resonance imaging; PCI, percutaneous coronary intervention.

**Echocardiographic information**

There was no difference in the echocardiographic data between the two groups, with the exception of the left ventricular internal dimension at end-systole (LVIDs), which was statistically significantly smaller in the HIV-positive compared to the HIV-negative sub-group (3.37 mm versus 3.96 mm). The systolic function was equally impaired in both groups. (Table 3).

| Variable, mean (SD) except where specified | HIV+ | HIV- | p-value |
|-------------------------------------------|------|------|---------|
| LA diameter (mm) (n = 48)                 | 3.47 (0.52) | 3.84 (0.67) | 0.124 |
| LA area (cm²) (n = 73)                    | 17.89 (4.28) | 19.58 (4.80) | 0.219 |
| LVIDs (mm) (n = 73)                       | **3.37 (0.54)** | **3.96 (0.90)** | **0.019** |
| LVIDd (mm) (n = 77)                       | 4.72 (0.49) | 5.11 (0.83) | 0.083 |
| Ejection fraction (%) (n = 86)            | 45.4% (11.56) | 44.3% (12.46) | 0.758 |
| E/e' (n = 69)                             | 12.18 (5.06) | 14.06 (8.22) | 0.4171 |
| Effusion: n (%) (n = 77)                  | 2 (13.3%) | 7 (11.3%) | 1 |

Bolded text = statistically significant. SD, standard deviation; LA, left atrium; LVIDs, left ventricular internal diameter end-systole; LVIDd, left ventricular internal dimension end-diastole; E/e', ratio between early mitral inflow velocity and mitral annular early diastolic velocity.

**HIV-specific information**

The median CD4⁺ count in those with available CD4⁺ results in the HIV-positive sub-group was 271 cells/mm³. Twenty-two patients (81.5%) had a CD4⁺ count < 500 cells/mm³, with a nadir CD4⁺ count of 41 cells/mm³. Seventeen (65.4%) patients were virally suppressed (HIV VL < 200 copies/mL) and thirteen (50%) had viral loads lower than detectable limits (HIV VL < 20 copies/mL). The majority of the HIV-positive participants were on ART at the time of the ACS event (20 patients; 66.7%), while eight (26.7%) were ART-naïve and two (6.7%) had defaulted their medication at the time of the event. Of the HIV-positive patients receiving ART, fifteen (75%) were on a non-nucleoside reverse transcriptase inhibitor (NNRTI) – based regimen and five (25%) were on a protease inhibitor (PI) – based regimen. (Table 4).
Table 4
Immunological and ART status of HIV-positive patients.

| Variable, n (%) except where specified | HIV+ |
|---------------------------------------|------|
| Viral load (copies/mL) (n = 26)        |      |
| Suppressed (< 200)                    | 17 (65.4%) |
| Unsuppressed (> 200)                  | 9 (34.6%)  |
| CD4+ count (cells/mm$^3$) (n = 27)    |      |
| Median (IQR)                          | 271 (355)  |
| ART status (n = 30)                   |      |
| Treated with ART at time of event     | 20 (66.7%) |
| ART-naïve                             | 8 (26.7%)  |
| Defaulted ARTs                        | 2 (6.7%)   |
| ART regimen (n = 20)                  |      |
| Tenofovir-emtricitibine-efavirenz     | 14 (70.0%) |
| Abacavir-lamivudine-efavirenz         | 1 (5.0%)   |
| Zidovudine-lamivudine-lopinavir/ritonavir | 4 (20.0%) |
| Stavudine-lamivudine-lopinavir/ritonavir | 1 (5.0%)  |

IQR, inter-quartile range; ART, anti-retroviral therapy

Management

There was no difference in the immediate or long-term management of the patients (Table 2b). Rates of thrombolysis in patients with STEMIs did not differ significantly between HIV-positive and HIV-negative patients.

Discussion

In this retrospective cross-sectional analysis of patient records at a large tertiary hospital in Cape Town, South Africa, the 12-month period prevalence of HIV in those hospitalised with ACS was 3.4% (95% CI 2.3–4.8). HIV-positive patients were younger, predominantly male, had a lower prevalence of medical comorbidities and a lower prevalence of a family history of CAD, even after adjusting for age and sex. HIV-positive patients experienced more STEMIs and single-vessel disease. The LAD was the most commonly affected coronary artery, translating into more LAD-territory myocardial infarctions. The majority of the HIV-positive patients in our study were immune-suppressed (CD4+ counts < 500 cells/mm$^3$) and virally-suppressed (VL < 200 copies/mL). Most HIV-positive patients were on ART at the
time of ACS event, with the majority of them on NNRTI-based ART. Immediate and long-term management
did not differ significantly between HIV-positive and HIV-negative patients. Our findings contribute data
on the prevalence and presentation of HIV in ACS from South Africa with the largest ART program in the
world and a rising rate of non-communicable disease-attributed morbidity and mortality [14].

The relative absence of traditional risk factors in the HIV-positive sub-group suggests additional
pathogenic mechanisms in these patients; one being the higher rates of sub-clinical dyslipidaemia seen
in HIV-positive individuals. HIV autopsy studies have shown evidence of premature CAD in HIV-positive
patients even before initiation of ART, as a result of complex dyslipidaemic patterns: reduced total serum
cholesterol, reduced high-density lipoprotein (HDL), reduced apolipoprotein B, and increased low-density
lipoprotein (LDL) [4]. Despite a lower prevalence of diagnosed dyslipidaemia in our HIV-positive sub-
group, we do not have data on their lipid profiles at the time of presentation for ACS, which may have
revealed a higher prevalence of sub-clinical dyslipidaemia. The fact that only five (17%) HIV-positive
patients in our study were receiving PIs, most strongly implicated in the causation of dyslipidaemia,
suggests that ART cannot be the only risk factor for dyslipidaemia [2]. Studies showing the beneficial role
of early ART-initiation in the prevention of CAD in HIV-positive individuals, as well as the increased risk of
CAD and other comorbidities associated with ART-interruption further support this notion [15]. Therefore,
it is plausible that it is the combined effect of HIV infection and certain ART drugs that results in complex
sub-clinical dyslipidaemic patterns in HIV-positive patients, thereby increasing their risk for CAD and
resultant ACS.

An additional suggested pathogenic mechanism for CAD in HIV-positive individuals is immune-system
dysfunction, which can be directly measured by the number of CD4+ lymphocytes in the body.
Lichtenstein et al. showed that a CD4+ count of less than 500 cells/mm³ is an independent risk factor for
CAD, with comparative attributable risk of approximately 20% - a figure similar to several other traditional
CAD risk factors [16]. The majority (81%) of patients in our study had CD4+ counts less than
500 cells/mm³ which suggests an increased risk of CAD in these patients. Current detectable viraemia
has been found to be a further risk factor for CAD, due to its contribution to an environment of persistent
chronic inflammation [15]. Even virally suppressed HIV-positive patients have higher levels of
inflammatory markers than those without HIV; thereby predisposing them to CAD [8].

The predominant presentation of single-vessel CAD and STEMIs in the HIV-positive patients in our study
(even after adjusting for age and sex) is most likely due to the unique histological characteristics of
coronary plaques in these patients. Virtual histology intravascular ultrasound analysis of HIV-positive
patients affected by ACS has shown a high prevalence of unstable plaque morphology that is rich in
necrotic tissue, less calcific, and has a thicker fibrous cap compared to that seen in traditional CAD [4].
Non-calcified plaques are more likely to rupture than calcific or mixed plaques, putting these patients at
higher risk of single-vessel STEMI than their HIV-negative counterparts [17]. This higher plaque
vulnerability is thought to be linked to the chronic inflammatory process of being infected with the HI
virus itself. Furthermore, Moran et al. found that HIV-positive patients with single-vessel disease had
higher Gensini Scores [18] than HIV-negative controls with single-vessel disease, indicating more severe
vessel stenosis in the former [17]. The presence of more extensive, more vulnerable non-calcific, fibro-fatty plaque could also explain the higher prevalence and earlier onset of ACS in the HIV-positive population.

The mild systolic dysfunction seen in both groups is in keeping with the echocardiographic changes expected after a myocardial infarction. We would expect more advanced diastolic dysfunction in our HIV-negative sub-group as a result of the increased prevalence of hypertension in this group. A study done in Cameroon comparing the left atrial remodelling in hypertensives compared to healthy participants showed the hypertensive patients to have a larger left atrial diameter, surface area and volume, indicating an altered diastolic function in these patients [19]. Although statistically nonsignificant, it is plausible that the 11 µmol/L higher mean serum creatinine in the HIV-negative sub-group can be explained by the increased prevalence of medical comorbidities in this group, resulting in a higher incidence of target-organ damage which may manifest as sub-clinical/clinical chronic kidney disease. Serum creatinine is reported in many studies as a prognostic marker for overall cardiac mortality. In a study by Matts et al. it was found that each nine µmol/L (0.1 mg/dL) rise in baseline serum creatinine had a 36% increased relative risk of future overall mortality and a 47% increased relative risk for future atherosclerotic CAD mortality (no confounding factors present) [20]. This potentially translates into a 44% increased relative risk of overall future mortality and a 57% increased relative risk for future atherosclerotic CAD mortality in the HIV-negative patients in our study. Such a finding in our study cannot be over-interpreted due to our small sample size.

As there is no current evidence for a change in immediate or long-term management of CAD and ACS based on HIV status, all patients in our study were treated similarly. Simvastatin coadministered with PIs are expected in increase simvastatin concentrations markedly due to CYP3A inhibition [21]. However, we noted that 80% of patients on PIs incorrectly received simvastatin. The more frequent prescription of calcium-channel blockers and thiazide diuretics in the HIV-negative sub-group is most likely as a result of the increased prevalence of hypertension in this population.

Overall, our findings were consistent with the literature. There is limited global data on the prevalence of HIV in people presenting with ACS, but our findings are similar to the 2.4% HIV prevalence found in the CAD sub-group (consisting of 581 patients) of all de novo cases of heart disease presenting to a tertiary hospital in Soweto, South Africa [22]. These values are significantly lower than both the 13.1% estimated national HIV-prevalence in South Africa in 2018 and the 7% prevalence of HIV in a population of people with ACS in a HIC such as Spain [11]. This may be due to the under-reporting of HIV in ACS in South Africa as evidenced by the large portion of untested patients in our study (Fig. 1) [1]. Furthermore, it may be due to other confounding factors; one being age: HIV-prevalence is highest in young adults whereas ACS primarily affects the elderly. Despite this, data from a study conducted in Québec, Eastern Canada, showed the incidence of ACS to be 3.88 in the HIV-positive cohort compared to 2.21 in the HIV-negative cohort per 1000 patient-years, irrespective of exposure to ART [23]. A study conducted in Boston, Massachusetts, showed increased ACS rates per 1000 person-years in HIV-positive vs HIV-negative patients (11.13 vs 6.98), even after adjusting for age, sex, race, hypertension, diabetes and dyslipidaemia
The demographic profile and CAD risk factor profile of the patients in our study was consistent with that seen in the literature. Furthermore, the type of ACS and number of involved coronary arteries of the HIV-positive patients in our study matched that seen in the literature. Various studies from the USA and France showed angiographic findings of fewer involved vessels and a greater burden of inflammatory plaque in the HIV-positive cases as compared to the HIV-uninfected cases [7]. Our findings of a predilection for LAD artery involvement in the HIV-positive patients are supported by those of Vachiat et al. who showed the LAD to be the most common culprit artery (60%) in HIV-positive patients with ACS [24]. The same proportion of HIV-positive and HIV-negative patients in our study underwent percutaneous coronary intervention (PCI), but we have no follow-up data on long-term success rates of such an intervention. A Spanish study showed a lower long-term success-rate in HIV-positive patients who underwent PCI compared to HIV-negative patients (75% versus 85% success-rate respectively) [25].

An interesting finding from our study was that despite a nonsignificant increased unadjusted prevalence of smoking seen in HIV-positive compared to HIV-negative patients, this finding was reversed when adjusting for age and sex. This finding could perhaps explain the heterogeneity in smoking data when comparing HIV-positive and HIV-negative patients with ACS. The majority of studies show a positive correlation between HIV-infection and smoking; however, when matching on age and sex, Dwyer et al found no difference in rates of smoking between HIV-positive and HIV-negative sub-groups [1, 26].

Our study has a number of limitations. First, the retrospective, observational design limits its ability to control for unmeasured confounders. Second, our sample size is limited which did not allow us to perform sub-group analyses. Third, we may have underestimated the HIV-prevalence within the ACS population due to the relative infrequent reporting of HIV-results. It is not routine for everyone presenting to a healthcare facility in South Africa to be tested for HIV, meaning that the actual prevalence of HIV within the ACS population might be higher than reported in our study. Last, we were confronted with missing data. CD4⁺ counts and viral loads were not available for all HIV-positive patients, and when available, were not always taken during the same admission as for the ACS event.

### Conclusions

In conclusion, we found that HIV-positive patients with ACS were younger, more likely to present with STEMI's and single-vessel disease, and had limited traditional ACS risk factors. This suggests additional pathogenic mechanisms for the development of CAD and ACS in patients with HIV; possibly attributed to the inflammation and immune-activation caused by infection with the HI virus itself. To date, ART is the most important intervention in reducing this inflammation and immune-activation [15]. Early initiation as well as wise selection of ART (taking into account individual clinical profile) should be priority in all patients with HIV. Baseline risk factors should be addressed early in the disease process. The benefit of the addition of antimicrobial translocation drugs is being explored as a possible treatment for HIV-positive patients with or even before the development of CAD [15]. This study highlighted the need for more widespread screening for HIV in patients with CAD, as well as the need for earlier detection of CAD.
in patients with HIV. It also highlighted the need for more specialised management of HIV-positive patients with ACS.

**Abbreviations**

CAD, coronary artery disease; HIC, high-income country; ACS, acute coronary syndrome; TBH, Tygerberg Hospital; SSA, Sub-Saharan Africa; CI, confidence interval; STEMI, ST-elevation myocardial infarction; OR, odd’s ratio; ART, anti-retroviral therapy; LMIC, low/middle-income country; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; ECG, electrocardiogram; ECM, Electronic Content Management System; NHLS, National Health Laboratory Service; SD, standard deviation; LAD, left anterior descending; LVIDs, left ventricular internal dimension at end-systole; VL, viral load; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PCI, percutaneous coronary intervention.

**Declarations**

**Ethics approval:**

Ethical approval for the study was obtained from the Human Research Ethics Committee of the Faculty of Medicine and Health Sciences of Stellenbosch University (U19/05/023).

**Consent for publication:**

Not applicable

**Availability of data and materials:**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests:**

The authors declare that they have no competing interests.

**Funding:**

No external funding was utilised.

**Authors’ contributions:**
ED conceived the study and edited the manuscript. CP developed the study protocol, managed data collection and coding, and was a major contributor in writing the manuscript. TE analysed the patient data. AD interpreted the data and contributed to editing the manuscript. All authors read and approved the final manuscript.

**Acknowledgements:**

The authors wish to thank Veshni Pillay-Fuentes Lorente for her help creating the study database and for her support and guidance throughout the project. We also acknowledge Peter Paul Robertse for his contribution to the study design.

**References**

1. Calvo M, Saubí N, Gatell JM, Miró O, Sánchez M, Foix A, et al. Clinical presentation of acute coronary syndrome in HIV infected adults: A retrospective analysis of a prospectively collected cohort. Eur J Intern Med. 2011;22:485–8. doi:10.1016/j.ejim.2011.02.017.

2. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: Time for a better understanding. J Am Coll Cardiol. 2013;61:511–23. doi:10.1016/j.jacc.2012.06.063.

3. Boccara F. Acute coronary syndrome in HIV-infected patients. Does it differ from that in the general population? Arch Cardiovasc Dis. 2010;103:567–9. doi:10.1016/j.acvd.2010.10.004.

4. Seecheran VK, Giddings SL, Seecheran NA. Acute coronary syndromes in patients with HIV. Coron Artery Dis. 2017;28:166–72. doi:10.1097/MCA.0000000000000450.

5. Khunnawat C, Mukerji S, Havlichek D, Touma R, Abela GS. Cardiovascular Manifestations in Human Immunodeficiency Virus-Infected Patients. Am J Cardiol. 2008;102:635–42. doi:10.1016/j.amjcard.2008.04.035.

6. Strijdom H, De Boever P, Walzl G, Essop MF, Nawrot TS, Webster I, et al. Cardiovascular risk and endothelial function in people living with HIV/AIDS: Design of the multi-site, longitudinal EndoAfrica study in the Western Cape Province of South Africa. BMC Infect Dis. 2017;17:1–9. doi:10.1186/s12879-016-2158-y.

7. Hyle EP, Mayosi BM, Middelkoop K, Mosepele M, Martey EB, Walensky RP, et al. The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: A systematic review. BMC Public Health. 2017;17:1–15. doi:10.1186/s12889-017-4940-1.

8. Bahrami H, Budoff M, Haberlen SA, Rezaeian P, Ketlogetswe K, Tracy R, et al. Inflammatory markers associated with subclinical coronary artery disease: The multicenter AIDS cohort study. J Am Heart Assoc. 2016;5:1–13. doi:10.1161/JAHA.116.003371.

9. Vedanthan R, Seligman B, Fuster V, Weiner MA, Kravis HR. Global perspective on Acute Coronary Syndrome: A Burden on the Young and Poor. Circ Res. 2014;114:1959–75.
10. Maluleke R. Mortality and causes of death in South Africa, 2016: Findings from death notification. Stats SA. 2016. https://www.statssa.gov.za/publications/P03093/P030932016.pdf. Accessed 22 May 2020.

11. Mululeke R. Mid-year population estimates 2018. Stats SA. 2018. http://www.statssa.gov.za/publications/P0302/P03022018.pdf. Accessed 4 April 2020.

12. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with human immunodeficiency Virus Disease. J Clin Endocrinol Metab. 2007;92:2506–12. doi:10.1210/jc.2006-2190.

13. WellSky International Ltd. JAC Computer Services Ltd. https://www.wellsky.org (2009). Accessed 23 September 2019.

14. Elfenlein J. Ranking of countries with the highest prevalence of HIV in 2000 and 2018. Statista. 2019. https://www.statista.com/statistics/270209/countries-with-the-highest-global-hiv-prevalence/. Accessed 22 April 2020.

15. Lacson J, Barnes R, Bahrami H. Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer. Curr Atheroscler Rep. 2017;19:18. doi:10.1007/s11883-017-0651-4.

16. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, et al. Low CD4 + T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient Study. Clin Infect Dis. 2010;51:435–47. doi:10.1086/655144.

17. Moran CA, Southmayd G, Devireddy CM, Quyyumi AA, Ofotokun I, Liberman HA, et al. Clinical and procedural characteristics of persons living with HIV presenting with acute coronary syndrome. AIDS. 2020;34:83. doi:10.1097/QAD.0000000000002393.

18. Rampidis GP, Benetos G, Benz DC, Giannopoulos AA, Buechel RR. A guide for Gensini Score calculation. Atherosclerosis. 2019;287:181–3. doi:10.1016/j.atherosclerosis.2019.05.012.

19. Corrine A, Gounoue S, Tamdja AD, Choukem S, Ba H, Aboubakar SM, et al. Echocardiographic left atrial remodelling and determinants of left atrial size in the early phase of high blood pressure: a comparative cross-sectional study in Douala, Cameroon. Cardiovasc J Afr. 2019;30:1–7. doi:10.5830/CVJA-2019-046.

20. Matts J, Karnegis J, Campos C, Fitch L, Johnson J, Buchwald H. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. J Fam Pract. 1993;5:497–503.

21. Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017;8:6–14. doi:10.1016/j.jcte.2017.01.004.

22. Stewart S, Ntsekhe M, Sliwa K, Thienemann F, Carrington MJ, Becker A. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J. 2011;33:866–74. doi:10.1093/eurheartj/ehr398.
23. Durand M, Sheehy O, Baril J, Lelorier J, Tremblay L. Association Between HIV, Infection. Antiretroviral Therapy, and Risk of Acute Myocardial Infarction: A Cohort and ‘be c’ s Public Nested Case–Control Study Using Que Health Insurance Database. J Acquir Immune Defic Syndr. 2011;57:245–53.

24. Vachiat A, McCutcheon K, Tsabedze N, Zachariah D, Manga P. Atherosclerotic plaque in HIV-positive patients presenting with acute coronary syndromes. Cardiovasc J Afr. 2019;30:203–7. doi:10.5830/CVJA-2019-016.

25. Martin-Reyes R, Galeote G, Moreno R, Sanchez-Recalde A, Lopez De Sa E, Lopez-Sendon J. Percutaneous coronary interventionism in patients infected with human immunodeficiency virus admitted for acute coronary syndrome: a case-control study. Med Clin (Barc). 2010;24:4–6; doi:10.1016/j.medcli.2010.05.008.

26. Dwyer EJO, Rao S, Emmanuel S, Carr A. Lower coronary plaque burden in patients with HIV presenting with acute coronary syndrome. Open Heart 2016;1–7; doi:10.1136/openhrt-2016-000511.

Figures
Figure 1

Diagram of the selection of patients for study inclusion